Thrombogenesis in sickle cell disease

Journal of Laboratory and Clinical Medicine

Volumn 137, Issue 6, 2001, Pages 398-407

  Tomer, Aaron ^a,b   Harker, Laurence A ^a   Kasey, Suha ^a   Eckman, James R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035370820     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.115450     Document Type: Article

References (53)

1. Diggs LW, Ching RE. Pathology of sickle cell anemia. South Med J 1934;27:839-49.
2. Diggs LW, Vorder Bruegge CF. Vascular occlusive mechanisms in sickle cell disease. J Nat Med Assoc 1954;46:46-9.
3. Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: Current concepts and unanswered questions. Blood 1991;77:1405-14.
4. Leslie J, Langler D, Serjeant GR, Serjeant BE, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol 1975;30:159-66.
5. Rickles FR, O'Leary DS. Role of coagulation system in pathophysiology of sickle cell disease. Arch Intern Med 1974;133:635-41.
6. Green D, Scott JP. Is sickle cell crisis a thrombotic event? Am J Hematol 1986;23:317-21.
7. Devine DV, Kinney TR, Thomas PF, Rosse WF, Greenberg CS. Fragment D-dimer levels: An objective marker of vasoocclusive crisis and other complications of sickle cell disease. Blood 1986;68:317-9.
8. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992;81:539-44.
9. Francis R, Patch J, McGehee W, Crout F. Elevated prothrombin F1.2 fragment in sickle cell disease: Further evidence for activation of coagulation in the steady state. Blood 1990; 76:161a.
10. Richardson SGN, Matthews KB, Stuart J. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979;41:95-103.
11. Alkjaesig N, Fletcher A, Joist H, Chaplin H Jr. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med 1976;88:440-9.
12. Leichtman DA, Brewer GJ. Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis: Evidence for intravascular coagulation. Am J Hematol 1978;5:183-90.
13. Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 1989; 19:101-11.
14. Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973;82:44-53.
15. Grupp RA, Glueck HI, Granger SM, Miller MA. Platelet function in sickle cell anemia. Thromb Res 1977;10:325-55.
16. Stuart MJ, Stockman JA, Oski FA. Abnormalities of platelet aggregation in the vasoocclusive crisis of sickle-cell anemia. J Pediatr 1974;85:629-32.
17. Mehta P, Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 1980;96:209-13.
18. Buchanan GR, Holtkamp CA. Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 1983;54:595-603.
19. Colman RW, Hirsh J, Marder V, Salzman EW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1994.
20. Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997;78:736-41.
21. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verstraete M, Fuster V, Topol EJ, editors. Cardiovascular Thrombosis: Thrombocardiology. Philadelphia: Lippincott-Raven; 1998. p. 3-22.
22. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins and platelets. Thromb Haemost 1988;59:1-6.
23. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
24. Shattil SJ, Hoxie JA, Cunningham MC, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985;260:11107-14.
25. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
26. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma-chain. Biochemistry 1984;23:1767-74.
27. Bevers EM, Comfurius P, Zwaal RFA. Platelet procoagulant activity: Physiological significance and mechanisms of exposure. Blood Rev 1991;5:146-54.
28. Govers-Riemslag JWP, Janssen MP, Zwaal RFA, Rosing J. Effect of membrane fluidity and fatty acid composition on the prothrombin-converting activity of phospholipid vesicles. Biochemistry 1992;31:10000-8.
29. Mann KG, Nesheim ME, Church WE, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990;76:1-16.
30. Thiagarajan P, Tait JF. Binding of annexin V/placental anti-coagulant protein I to platelets. J Biol Chem 1990;265: 17420-3.
31. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arteriosclerosis Thromb 1992;12:1475-87.
32. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet alpha-granule release in vivo. Blood 1981;58:607-18.
33. Frelinger ALI, Lam S-T, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988;263:12397.
34. Nieuwenhuis HK, Van Oosterhout JJG, Rozemuller E, Van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: Evidence that a secreted 53,000 molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987;70:838-45.
35. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989;264:17049-57.
36. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994;123:741-8.
37. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations. Blood 1996;88: 1873-80.
38. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and betathalassemia. Thromb Haemost 1996;70:322-7.
39. Dalen JE, Hirsh J. Fourth ACCP consensus conference on antithrombotic therapy. Chest 1995;108:225S-522S.
40. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
41. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of aeschemia. Lancet 1996;348:1329-39.
42. Salvaggio Je, Arnold CA, Banov CH. Long-term anticoagulation in sickle-cell disease. N Engl J Med 1963;269: 182-6.
43. Chaplin H Jr, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disese pain crises. Thromb Haemost 1980;43:218-21.
44. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983;102:781-4.
45. Zago M, Costa F, Ismel S, Tone L, Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984;72:61-4.
46. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984;51:303-6.
47. Osamo ND, Photiades DP, Famadu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1998;66: 102-7.
48. Leslie J, Langler D, Serjeant GR, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. BMJ 1975;30:159-66.
49. Mills DCB. ADP receptors on platelets. Thromb Haemost 1996;76:835-56.
50. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-43.
51. Cabannes R, Lonsdorffer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind study of ticlopidine in preventive treatment of sickle-cell disease crisis. Agents Actions 1984;15(suppl):199-212.
52. Harker LA, Hanson SR. Experimental strategies for assessing antithrombotic benefits and hemorrhagic risks of novel antithrombotic agents. In: Sasahara A, Loscalzo J, editors. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker; 1997. p. 29-48.
53. Harker LA, Kelly AB, Hanson SR, et al. Interruption of vascular thrombus formation and vascular lesion formation by dietary ω-3 fatty acids in fish oil in nonhuman primates. Circulation 1993;87:1017-29.